Reye’s Syndrome and Related Chemical Toxicity

  • Lawrence C. Trost
  • John J. Lemasters


Valproic Acid Mitochondrial Permeability Transition Isovaleric Acid Metabolic Crisis Calcein Fluorescence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aprille, J. R., 1977, Reye’s syndrome: Patient serum alters mitochondrial function and morphology in vivo, Science 197:908–910.PubMedGoogle Scholar
  2. Beales, D., and McLean, A. E. M., 1996, Protection in the late stages of paracetamol-induced liver cell injury with fructose, cyclosporin A, and trifluoperazine, Toxicology 107:201–208.CrossRefPubMedGoogle Scholar
  3. Becker, C.-M., and Harris, R. A., 1983, Influence of valproic acid on hepatic carbohydrate metabolism and lipid metabolism, Arch. Biochem. Biophys. 223:381–392.CrossRefPubMedGoogle Scholar
  4. Bernardi, P., Broekemeier, K. M., and Pfeiffer, D. R., 1994, Recent progress on regulation of the mitochondrial permeability transition pore: A cyclosporin-sensitive pore in the inner-mitochondrial membrane, J. Bioenerg. Biomembr. 26:509–517.CrossRefPubMedGoogle Scholar
  5. Biban, C., Tassani, V, Toninello, A., Siliprandi, D., and Siliprandi, N., 1995, The alterations in the energy-linked properties induced in rat liver mitochondria by acetylsalicylate are prevented by cyclosporin A or Mg2-, Biochem. Pharmacol. 50:497–500.CrossRefPubMedGoogle Scholar
  6. Billington, D., Osmundsen, H., and Sherratt, H. S. A., 1978, Mechanisms of the metabolic disturbances caused by hypoglycin and by pent-4-enoic acid in vivo studies, Biochem. Pharm. 27:2879–2890.PubMedGoogle Scholar
  7. Bohles, H., Sewell, A. C., and Wenzel, D., 1996, The effect of carnitine supplementation in valproate-induced hyperammonemia, Acta Paediat. 85:446–449.PubMedGoogle Scholar
  8. Borison, H. L., Pendleton, J., Jr., McCarthy, L. E., 1974, Central vs systemic neurotoxicity of hypoglyxin (ackee toxin) and related substances in the cat, J. Pharmacol. Exp. Ther. 190:327–333.PubMedGoogle Scholar
  9. Bourgeois, B. F. D., 1989, Clinical use, in Antiepileptic Drugs 3rd ed., (R. H. Levy, F. E. Dreifuss, R. M. Mattson, B. S. Meldrum, and J. K. Penry, Eds.), Raven, New York, pp. 633–642.Google Scholar
  10. Bressler, R., Corredor, C., and Brendel, K., 1969, Hypoglycin and hypoglycin-like compounds, Pharmacol. Rev. 21:105–130.PubMedGoogle Scholar
  11. Brody, T. M., 1956, Action of sodium salicylate and related compounds on tissue metabolism in vitro, J. Pharmacol. Exp. Ther. 117:39–51.PubMedGoogle Scholar
  12. Broekemeier, K. M., and Pfeiffer, D. R., 1995, Inhibition of the mitochondrial permeability transition by cyclosporin A during long time frame experiments: A relationship between pore opening and the activity of mitochondrial phospholipases, Biochemistry 34:16440–16445.CrossRefPubMedGoogle Scholar
  13. Broekemeier, K. M., Schmid, O. C., Schmid, H. H., and Pfeiffer, D. R., 1985, Effects of phospholipase A2 inhibitors on ruthenium red-induced Ca2+ release from mitochondria, J. Biol. Chem. 260:105–113.PubMedGoogle Scholar
  14. Broekemeier, K. M., Dempsey, M. E., and Pfeiffer, D. R., 1989, Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria, J. Biol. Chem. 264:7826–7830.PubMedGoogle Scholar
  15. Broekemeier, K. M., Carpenter, D. L., Reed, D. J., and Pfeiffer, D. R., 1992, Cyclosporin A protects hepatocytes subjected to high Ca2+ and oxidative stress, FEES Lett. 304:192–194.Google Scholar
  16. Brown, R. E., and Forman, D. T., 1982, The biochemistry of Reye’s syndrome, CRC Crit. Rev. Clin. Lab. Sci. 17:247–297.Google Scholar
  17. Casteels-Van Daele, M., 1991, Reye’s syndrome or side-effects of anti-emetics? Eur. J. Pediatr. 150:456–459.PubMedGoogle Scholar
  18. Chabrol, B., Mancini, J., Chretien, D., Rustin, P., Munnich, A., and Pinsard, N., 1994, Valproate-induced hepatic failure in a case of cytochdrome c oxidase deficiency, Eur. J. Pediatr. 153:133–135.PubMedGoogle Scholar
  19. Chacon, H., Ulrich, R., and Acosta, D., 1992, Digitized-fluorescence-imaging study of mitochondrial Ca2+ increase by doxorubicin in cardiac myocytes, Biochem. J. 281:871–878.PubMedGoogle Scholar
  20. Corkey, B. E., Geschwind, J.-F., Deeney, J. T, Hale, D. E., Douglas, S. D., and Kilpatrick, L., 1991, Ca2+ responses to interleukin 1 and tumor necrosis factor in cultured human skin fibroblasts, J. Clin. Invest. 87:778–786.PubMedGoogle Scholar
  21. Coulter, D. E., 1991, Carnitine, valproate, and toxicity, J. Child. Neurol. 6:7–14.PubMedGoogle Scholar
  22. Crompton, M., Ellinger, H., and Costi, A., 1988, Inhibition by cyclosporin A of Ca2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress, Biochem. J. 255:357–360.PubMedGoogle Scholar
  23. Danan, G., Trunet, P., Bernuau, J., Degott, C., Babany, G., Pessayre, D., Rueff, B., and Benhamou, J. P., 1985, Pirprofen-induced fulminant hepatitis, Gastroenterology 89:210–213.PubMedGoogle Scholar
  24. DeVivo, D. C., and Keating, J. P., 1975, Reye’s syndrome, Adv. Pediatr. 22:175–229.Google Scholar
  25. Duerksen, D. R., Jewell, L. D., Mason, A. L., and Bain, V. G., 1997, Co-existence of hepatitis A and adult Reye’s syndrome, Gut 41:121–124.PubMedGoogle Scholar
  26. Duffy, J., Glasgow, J. R, Patterson, C. C., Clarke, M. J., and Turner, I.F.,1991, A sibling-controlled study of intelligence and academic performance following Reye’s Syndrome, Dev. Med. Child. Neurol. 33:811–815.Google Scholar
  27. Elpeleg, O. N., Christensen, E., Hurvitz, H., and Branski, D., 1990, Recurrent, familial Reye’s-like syndrome with a new complex amino and organic aciduria, Eur. J. Ped. 149:709–712.Google Scholar
  28. Flower, R. J., Moncada, S., Vane, J. R., 1985, Analgesic-antipyretics and anti-inflammatory agents: Drugs employed in the treatment of gout, in: The Pharmacological Basis of Therapeutics, 7th ed. (A. G. Gillman, L. S. Goodman, T. W. Rall, and F. Murad, Eds.), Macmillan, New York, pp. 674–715.Google Scholar
  29. Fournier, N., Ducet, G., and Crevat, A., 1987, Action of cyclosporine on mitochondrial calcium fluxes, J. Bioenerg. Biomembr. 19:297–303.CrossRefPubMedGoogle Scholar
  30. Fromenty, B., and Pessayre, D., 1995, Inhibition of mitochondrial β-oxidation as a mechanism of hepatotoxicity, Pharmacol. Ther. 67:101–154.CrossRefPubMedGoogle Scholar
  31. Gasbarrini, A., Borle, A. B., and Van Theil, D. H., 1993, Ca2- antagonists do not protect isolated perfused rat hepatocytes from anoxic injury, Biochim. Biophys. Acta 117:1–7.Google Scholar
  32. Gerber, N., Dickinson, R. G., Harland, R. C., Lynn, R. K., Houghton, D., Antonias, J. I., and Schimschock, J. C., 1979, Reye’s-like syndrome associated with valproic acid therapy, J. Pediat. 95:142–144.PubMedGoogle Scholar
  33. Glasgow, A. M., and Chase, H. P., 1975, Production of the features of Reye’s syndrome in rats with 4-pentenoic acid, Pediat. Res. 9:133–138.PubMedGoogle Scholar
  34. Glasgow, J. F. T., and Moore, R., 1993, Reye’s syndrome 30 years on, BMJ 307:950–951.PubMedGoogle Scholar
  35. Heubi, J. E., Partin, J. C., Partin, J. S., and Schubert, W. K., 1987, Reye’s syndrome: Current concepts, Hepatology 7:155–164.PubMedGoogle Scholar
  36. Hoek, J. B., Walajtys-Rode, E., and Wang, X., 1997, Hormonal stimulation, mitochondrial Ca2+ accumulation, and the control of the mitochondrial permeability transition in intact hepatocytes, Mol. Cell. Biochem. 174:173–179.CrossRefPubMedGoogle Scholar
  37. Hou, T. W., Chou, S. P., and Wang, T. R., 1996. Retubolic functions and liver histopathology in Reye-like illnesses, Actu Pediatrica 85:1053–1057.Google Scholar
  38. Imberti, R., Nieminen, A.-L., Herman, B., and Lemasters, J. J., 1992, Synergism of cyclosporin A and phospholipase inhibitors in protection against lethal injury to rat hepatocytes from oxidant chemicals, Rex. Commun. Chem. Pathol. Pharmacol. 78:27–38.Google Scholar
  39. Imberti, R., Nieminen, A.-L., Herman, B., and Lemasters, J. J., 1993, Mitochondrial and glycolytic dysfunction in lethal injury to hepatocytes by t-buylhydroperoxide: Protection by fructose, cyclosporin A, and trifluoperazine, J. Pharmacol. Exp. Ther. 265:392–400.PubMedGoogle Scholar
  40. Jezequel, A. M., Bonazzi, P., Novelli, G., Venturini, C., and Orlandi, F., 1984, Early structural and functional changes in liver of rats treated with a single dose of valproic acid, Hepatology 4:1159–1166.PubMedGoogle Scholar
  41. Kamp, F., and Hamilton, J. A., 1992, pH gradients across phospholipid membranes caused by fast flip-flop of unionized fatty acids, Proc. Natl. Acad. Sci. USA 89:11367–11370.PubMedGoogle Scholar
  42. Kamp, F., Westerfhoff, H. V., and Hamilton, J. A., 1993, Movement of fatty acids, fatty acid analogues, and bile acids across phospholipid bilayers, Biochemistry 32:11074–11086.PubMedGoogle Scholar
  43. Kesterson, J. W., Granneman, G. R., and Machinist, J. M., 1984, The hepatotoxicity of valproic acid and its metabolites in rats: I. Toxicologic, biochemical, and histopathologic studies, Hepatology 4:1143–1152.PubMedGoogle Scholar
  44. Koga, Y., Yoshida, I., Kimura, A., Yoshino, M., Yamashita, F., and Sinniah, D., 1987, Inhibition of mitochondrial function by Margosa oil: Possible implications in the pathogenesis of Reye’s syndrome, Pediat. Res. 22:184–187.PubMedGoogle Scholar
  45. Kroemer, G., Dallaporta, B., and Resche-Rigon, M., 1998, The mitochondrial death/life regulator in apoptosis and necrosis, Ann. Rev. Physiol. 60:619–642.Google Scholar
  46. Lam, C. W., Lou, C. H., Williams, J. C., Chan, Y. W, and Wong, L., 1997, Mitochondrial mxopathy, enceptralopxathy, lactic acidosis, and stroke like episodes (MELAS) triggered by vulprocute therapy, European J. Pediatrics, 156:562–4.Google Scholar
  47. Landon, E. J., Naukam, R. J., and Sastry, B. V. R., 1986, Effects of calcium channel blocking agents on calcium and centrilobular necrosis in the liver of rats treated with hepatotoxic agents, Biochem. Pharmacol. 35: 697–705.CrossRefPubMedGoogle Scholar
  48. Lapidus, R. G., and Sokolove, P. M, 1992, Inhibition by spermine of the inner membrane permeability transition of isolated rat heart mitochondria, FEBS Lett. 313:314–318.CrossRefPubMedGoogle Scholar
  49. Lapidus, R. G., and Sokolove, P. M., 1993, Spermine inhibition of the permeability transition of isolated rat liver mitochondria:An investigation of mechanism, Arch. Biochem. Biophys. 306:246–253.CrossRefPubMedGoogle Scholar
  50. Lemasters, J. J., Nieminen, A.-L., Qian, T., Trost, L. C., Elmore, S. P., Nishimura, Y., Crowe, R. A., Cascio, W. E., Bradham, C. A., Brenner, D. A., and Herman, B., 1998, The mitochondrial permeability transition in necrosis, apoptosis, and autophagy, Biochim. Biophys. Acta 1366:177–196.PubMedGoogle Scholar
  51. Lichtenstein, P. K., Heubi, J. E., Daughterty, C. C., Farrell, M. K.., Sokol, R. J., Rothbaum, R. J., Suchy, F. J., and Balistreri, W. F., 1983, Grade I Reye’s syndrome: A frequent cause of vomiting and liver dysfunction after varicella and upper-respiratory-tract infection, New Engl. J. Med. 309:133–139.PubMedGoogle Scholar
  52. Loscher, W., Wahnschaffe, U., Honack, D., Wittfoht, W., and Nau, H., 1992, Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver: I. Biochemical, histopathological, and pharmacokinetic studies. Epilepsy Res. 13:187–198.CrossRefPubMedGoogle Scholar
  53. Maheady, D. C., 1989, Reye’s syndrome: Review and update, J. Pediat. Health Care 3:245–250.Google Scholar
  54. Martens, M. E., and Lee, C.-P., 1984, Reye’s syndrome: Salicylates and mitochondrial functions, Biochem. Pharmacol. 33:2869–2876.CrossRefPubMedGoogle Scholar
  55. Martens, M. E., Chang, C. H., and Lee, C. P., 1986, Reye’s s yndrome: Mitochondrial swelling and Ca2+ release induced by Reye’s plasma, allantoin, and salicylate, Arch. Biochem. Biophys. 244:773–786.CrossRefPubMedGoogle Scholar
  56. Matsuda, N., Morit,, Nakamura, H., and Shigekawv, M., 1995, Mechanisms of the deoxygenation-induced calcium overload in cardiac myocytes:dependence on p11c, Surgical Research 99:712–8.Google Scholar
  57. Matsumoto, J., Ogawa, H., Maeyama, R., Okudaira, K., Shinka, T., Kuhara, T., and Matsumoto, I., 1997, Successful treatment by direct hemoperfusion of coma possibly resulting from mitochondrial dysfunction in acute valproate intoxication, Epilepsia 38:950–953.CrossRefPubMedGoogle Scholar
  58. Mauger, J. P., and Claret, M., 1988, Calcium channels in hepatocytes, J. Hepatol. 7:278–282.CrossRefPubMedGoogle Scholar
  59. McTague, J. A., and Forney, R., Jr., 1994, Jamaican vomiting sickness in Toledo, Ohio, Ann. Emerg. Med. 23:1116–1118.PubMedGoogle Scholar
  60. McCune, S. A., Durant, P. J., Flanders, L. E., and Harris, R. A., 1982, Inhibition of hepatic gluconeogenesis and lipogenesis by benzoic acid, p-tert-butylbenzoic acid, and a structurally related hypolipidemic agent, SC-33459, Arch. Biochem. Biophys. 214:124–133.CrossRefPubMedGoogle Scholar
  61. Melegh, B., and Trombitus, K., 1997, Volprocite treatment induces lipid globule accemulation with ultrastrucural adnormalities of mitochondria in skeletal muscle, Neuropediatrics 28:257–61.PubMedGoogle Scholar
  62. Michael, A. D., and Whiting, R. L., 1989, Cellular action of nicardipine, Am. J. Cardiol. 64:3H–7H.Google Scholar
  63. Mitchell, J. C., 1974, The posthumous misfortune of Captain Bligh of the ′Bounty: ″ Hypoglycemia from Blighia, Diabetes 23:919–920.PubMedGoogle Scholar
  64. Mitchell, P., 1979, Keilin’s respiratory chain concept and its chemiosmotic consequences. Science 206: 1148–1159.PubMedGoogle Scholar
  65. Mitchell, R. A., Ram, M. L., Arcinue, E. L., and Chang, C. H., 1980, Comparison of cytosolic and mitochondrial hepatic enzyme alterations in Reye’s syndrome, Pediat. Res. 14:1216–1221.PubMedGoogle Scholar
  66. Morales, A. R., Bourgeois, C. H., and Chulacharit, E., 1971, Pathology of the heart in Reye’s syndrome (encephalopathy and fatty degeneration of the viscera), J. Cardiol. 27:314–317.Google Scholar
  67. Mortensen, P. B., Gregersen, N., Kolvraa, S., and Christensen, E., 1980, The occurrence of C6-C10-dicarboxylic acids in urine from patients and rats treated with dipropylacetate, Biochem. Med. 24:153–161.CrossRefPubMedGoogle Scholar
  68. Nieminen, A.-L., Gores, G. J., Bond, J. M., Imberti, R., Herman, B., and Lemasters, J. J., 1992, A novel cytotoxicity assay using a multiwell fluorescence scanner, Toxicol. Appl. Pharmacol. 115:147–155.CrossRefPubMedGoogle Scholar
  69. Nieminen, A.-L., Saylor, A. K., Tesfai, S. A., Herman, B., and Lemasters, J. J., 1995, Contribution of the mitochondrial permeability transition to lethal injury after exposure of hepatocytes to t-butylhydroperoxide, Biochem J. 307:99–106.PubMedGoogle Scholar
  70. Ozawa, H., Sasaki, M., Sugai, K., Hashimoto, T, Matsuda, H., Takashima, S., Uno, A., and Okawa, T, 1996, Single-photon emission CT and MR findings in Kluver-Bucy syndrome after Reye’s syndrome, AJNR 18:540–542.Google Scholar
  71. Partin, J. S., Daugherty, C. C.. McAdams, A. J., Partin, J. C., and Schubert, W. K., 1984, A comparison of liver ultrastructure in salicylate intoxication and Reye’s syndrome, Hepatology 4:687–690.PubMedGoogle Scholar
  72. Partin, J. C., Shubert, W. K., and Partin, J. S., 1971, Mitochondrial ultrastructure in Reye’s syndrome (encephalopathy and fatty degeneration of the viscera), New Engl. J. Med. 285:1339–1343.PubMedGoogle Scholar
  73. Pastorino, J. G., Snyder, J. W., Serroni, A., Hoek, J. B., and Farber, J. L., 1993, Cyclosporin and carnitine prevent the anoxic death of cultured hepatocytes by inhibiting the mitochondrial permeability transition, J. Biol. Chem. 268:13791–13798.PubMedGoogle Scholar
  74. Petronilli, V, Cola, C., Massari, S., Colonna, R., and Bernardi, P., 1993, Physiological effectors modify voltage sensing by the cyclosporin A-sensitive permeability transition pore of mitochondria, J. Biol. Chem. 268:21939–21945.PubMedGoogle Scholar
  75. Petronilli, V, Costantini, P., Scorrano, L., Colonna, R., Passamonti, S., and Bernardi, P., 1994a, The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols, J. Biol. Chem. 269:16638–16642.PubMedGoogle Scholar
  76. Petronilli, V, Nicolli, A., Costantini, P., Colonna, R., and Bernardi, P., 1994b, Regulation of the permeability transition pore, a voltage-dependent mitochondrial channel inhibited by cyclosporin A, Biochim. Biophys. Acta. 1187:255–259.PubMedGoogle Scholar
  77. Pinsky, P. F., Hurwitz, E. S., Schonberger, L. B., and Gunn, W. J., 1988, Reye’s syndrome and aspirin: Evidence for a dose-response effect, JAMA 260:657–661.CrossRefPubMedGoogle Scholar
  78. Ponchaut, S., and Veitch, K., 1993, Valproate and mitochondria, Biochem. Pharmacol. 46:199–204.CrossRefPubMedGoogle Scholar
  79. Qian, T., Nieminen, A.-L, Herman, B., and Lemasters, J. J., 1997, The role of pH1, Na+, and the mitochondrial permeability transition in reperfusion injury to rat hepatocytes: Protection by cyclosprin A and glycine, Am. J. Physiol. 273:C1783–C1792.PubMedGoogle Scholar
  80. Ray, S. D., Kamendulis, L. M., Gurule, M. W., Yorkin, R. D., and Corcoran, G. B., 1993, Ca2+ antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminophen, FASEB J. 7:453–463.PubMedGoogle Scholar
  81. Reye, R. D. K., Morgan, G., and Baral, J., 1963, Encephalopathy and fatty degeneration of the viscera: A disease entity in childhood, Lancet ii. 749–752.Google Scholar
  82. Rodgers, G. C., Jr., Weiner, L. B., and McMillan, J. A., 1982, Salicylate and Reye’s syndrome, Lancet, i:616.Google Scholar
  83. Schon, E. A., Hirano, M., and DiMurro’s, 1994, Mitochondrial ecepha;p,yopathics: clinical and molecular analysis, J. Bioenergetics Biomembranes 26:291–9.Google Scholar
  84. Schonfeld, P., and Bohnensack, R., 1997, Fatty acid-promoted mitochondrial permeability transition by membrane depolarization and binding to the ADP/ATP carrier, FEBS Lett. 420:167–170.PubMedGoogle Scholar
  85. Segalman, T. Y., and Lee, C. P., 1982, Reye’s syndrome: Plasma-induced alterations in mitochondrial structure and function, Arch. Biochem. Biophys. 214:522–530.CrossRefPubMedGoogle Scholar
  86. Shaw, G. R., and Anderson, W. R., 1991, Multisystem failure and hepatic microvesicular fatty metamorphosis associated with tolmetin ingestion, Arch Pathol. Lab. Med. 115:818–823.PubMedGoogle Scholar
  87. Sherratt, H. S. A., 1986, Hypoglycin, the famous toxin of the unripe Jamaican ackee fruit, TIPS May: 186–191.Google Scholar
  88. Shirley, M. A., Hu, P., and Baillie, T. A., 1993, Stereochemical studies on the β-oxidation of valproic acid in isolated rat hepatocytes, Drug Metab. Dispos. 21:580–586.PubMedGoogle Scholar
  89. Sinniah, D., and Baskaran, G., 1981, Margosa oil poisoning as a cause of Reye’s syndrome, Lancet i:487–489.Google Scholar
  90. Sinniah, D., Schwartz, P. H., Mitchell, R. A., and Arcinue, E. L., 1985, Investigation of an animal model of a Reye’s-like syndrome caused by margosa oil, Pediat. Res. 19:1346–1355.PubMedGoogle Scholar
  91. Sippel, H., Stauffert, I., and Estler, C.-J., 1993, Protective effect of various calcium antagonists against an experimentally induced calcium overload in isolated hepatocytes, Biochem. Pharmacol. 46:1937–1944.CrossRefPubMedGoogle Scholar
  92. Skellon, J. H., Thornburn, S., Spence, J., and Chatterjee, S. N., 1962, The fatty acids of neem oils and their reduction products, J. Sci. Food Agric. 13:639–643.Google Scholar
  93. Solem, L. E., Heller, L. J., and Wallace, K. B., 1996, Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin, J. Mot Cell. Cardiol. 28: 1023–1032.Google Scholar
  94. Starko, K. M., and Mullick, F. G., 1983, Hepatic and cerebral pathology findings in children with fatal salicylate intoxication: Further evidence for a causal relation between salicylate and Reye’s syndrome, Lancet i: 326–329.Google Scholar
  95. Starko, K. M., Ray, C. G., Dominguez, L. B., Stromberg, W. L., and Woodall, D. F, 1980, Reye’s syndrome and salicylate use, Pediatrics 66:859–864.PubMedGoogle Scholar
  96. Sugimoto, T., Araki, A., Nishida, N., Sakane, Y, Woo, M., Takeuchi, T., and Kobayashi, Y., 1987, Hepatoxicity in rat following administration of valproic acid: Effect of 1-carnitine supplementation, Epilepsia 28:373–377.PubMedGoogle Scholar
  97. Sullivan-Bolynai, J. Z., and Corey, L., 1981, Epidemiology of Reye’s syndrome, Epidemiol. Rev. 3:1–26.Google Scholar
  98. Surgeon General’s advisory on the use of salicylates and Reye’s syndrome, 1982, MMWR 31:289–290.Google Scholar
  99. Tanaka, K., Isselbacher, K. J., and Shih, V., 1972, Isovaleric and alpha-methylbutyric acidemias induced by hypoglycin A: Mechanism of Jamaican vomiting sickness, Science 175:69–71.PubMedGoogle Scholar
  100. Tomasova, H., Nevoral, J., Pachi, J., and Kind, V., 1984, Aspirin esterase activity and Reye’s syndrome. Lancet ii:43.Google Scholar
  101. Tomoda, T, Takeda, K., Kurashige, T., Enzan, H., and Miyahara, M., 1994, Acetylsalicylate (ASA)-induced mitochondrial dysfunction and its potentiation by Ca2+, Liver 14:103–108.PubMedGoogle Scholar
  102. Tonsgard, J. H., and Huttenlocher, P. R., 1982, Reye’s syndrome, in Recent Advances in Clinical Neurology (W. B. Matthews and G. H. Glaser, Eds.), Churchill-Livingstone, Edinburgh, pp. 169–192.Google Scholar
  103. Treem, W. R., Shoup, M. E., Hale, D. E., Bennett, M. J., Rinaldo, P., and Millington, D. S., 1996, Acute fatty liver of pregnancy, hemolysis, elevated liver enzymes, and low platelets syndrome, and long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency, Am. J. Gastroenterol. 91:2293–2300.PubMedGoogle Scholar
  104. Treon, S. P., and Broitman, S. A., 1992, Monoclonal antibody therapy in the treatment of Reye’s syndrome, Med. Hypo. 39:238–242.Google Scholar
  105. Trost, L. C., and Lemasters, J. J., 1996, The mitochondrial permeability transition: A new pathophysiological mechanism for Reye’s syndrome and toxic liver injury, J. Pharmacol. Exp. Ther. 278:1000–1005.PubMedGoogle Scholar
  106. Trost, L. C., and Lemasters, J. J., 1997, Role of the mitochondrial permeability transition in salicylate toxicity to cultured rat hepatocytes: Implications for the pathogenesis of Reye’s syndrome, Toxicol. Appl. Pharmacol. 147:431–441.CrossRefPubMedGoogle Scholar
  107. Turnbull, D. M., Bone, A. J., Bartlett, K., Koundakjian, P. P., and Sheratt, H. S. A., 1983, The effects of valproate on intermediary metabolism in isolated rat hepatocytes and intact rats, Biochem. Pharmacol. 32:1887–1892.CrossRefPubMedGoogle Scholar
  108. Uchino, H., Elmer, E., Uchino, K., Lindvall, O., and Siesjo, B. K., 1995, Cyclosporin A dramatically ameliorates CA1 hippocampal damage following transient forebrain ischaemia in the rat, Acta Physiol. Scand. 155: 469–471.PubMedGoogle Scholar
  109. Ulrich, R. G., Bacon, J. A., Branstetter, D. G., Cramer, C. T, Funk, G. M., Hunt, C. E., Petrella, D. K., and Sun, E, L., 1994, Induction of a hepatic toxic syndrome in the dutch-belted rabbit by a quinoxalinone anxiolytic, Toxicology 98:187–198.Google Scholar
  110. Valencia, A. M., Quevedo, F. W., and Quintos, L. S., 1997, Reye’s syndrome: Not of historical interest only, Pediat. Infect. Dis. J. 16:1011–1012.Google Scholar
  111. Visentin, M., Salmona, M., and Tacconi, M. T., 1995, Reye’s and Reye’s-like syndromes, drug-related diseases? (Causative agents, etiology, pathogenesis, and therapeutic approaches), Drug Met. Rev. 27:517–539.Google Scholar
  112. Waldman, R. J., Hall, W. N., McGee, H., and Van Amburg, G., 1982, Aspirin as a risk factor in Reye’s syndrome, JAMA 247:3089–3094.CrossRefPubMedGoogle Scholar
  113. Willmore, L. J., Triggs, W. J., and Pellock, J. M., 1991, Valproate toxicity:Risk-screening strategies, J. Child Neural. 6:3–6.Google Scholar
  114. Yamamoto, M., and Nakamura, Y., 1994, Inhibition of β-oxidation by 3-mercaptopropionic acid produces features of Reye’s syndrome in perfused rat liver, Gastroenterology 107:517–524.PubMedGoogle Scholar
  115. Yoshida, Y, Singh, I., and Darby, C. P., 1992, Effect of salicylic acid and calcium on mitochondrial functions, Acta Neurol. Scand. 85:191–196.PubMedGoogle Scholar
  116. You, K.-S., 1983, Salicylate and mitochondrial injury in Reye’s syndrome, Science 221:163–165.PubMedGoogle Scholar
  117. Zimmerman, H. J., and Ishak, K. G., 1982, alproate-induced hepatic injury: Analysis of 23 fatal cases, Hepatology 2:591–597.PubMedGoogle Scholar
  118. Zoratti, M., and Szabó, I., 1995, The mitochondrial permeability transition, Biochim. Biophys. Acta 1241: 139–176.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Lawrence C. Trost
    • 1
  • John J. Lemasters
    • 2
  1. 1.Curriculum in ToxicologyUniversity of North Carolina at Chapel HillChapel Hill
  2. 2.Department of Cell Biology and AnatomyUniversity of North Carolina at Chapel HillChapel Hill

Personalised recommendations